hit counter
Assembly Biosciences, Inc. (ASMB) Stock News Sentiment & Price - Sentifly
ASMB - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Assembly Biosciences, Inc. (ASMB)

USA
Biotechnology
NASDAQ
ASMB Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ASMB Latest news
GlobeNewsWire
Neutral
Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
2021-10-19 07:30

MENDHAM, N.J., and SOUTH SAN FRANCISCO, Calif, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Antios Therapeutics, Inc. and Assembly Biosciences, Inc. (Nasdaq: ASMB) today announced that the companies have entered into a clinical collaboration agreement to evaluate a triple combination treatment in patients with chronic hepatitis B virus (HBV) infection. A single cohort in the ongoing Antios Phase 2a ANTT201 clinical trial will evaluate ATI-2173, Antios' investigational proprietary active site polymerase inhibitor nucleotide (ASPIN), vebicorvir (VBR), Assembly Bio's investigational lead core inhibitor candidate, and tenofovir disoproxil fumarate, a nucleotide reverse transcriptase inhibitor.

GlobeNewsWire
Neutral
Assembly Bio Announces October Conference Participation
2021-10-06 08:00

SOUTH SAN FRANCISCO, Calif., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), announced participation in the below upcoming conferences focused on HBV:

GlobeNewsWire
Neutral
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2021-10-01 18:04

SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced grants of stock options to two new employees to purchase an aggregate of 16,000 shares of the Company's common stock with an exercise price of $3.46 per share, the closing price of Assembly Bio's common stock on October 1, 2021. The stock options were granted as material inducements to the new employees to accept the Company's offers of employment.

Pulse2
Negative
ASMB Stock: Over 15% Decrease Pre-Market Explanation
2021-09-02 07:51

The stock price of Assembly Biosciences, Inc. (Nasdaq: ASMB) fell by over 15% pre-market. This is why it happened.

GlobeNewsWire
Neutral
Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158
2021-09-01 16:02

--Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study --Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates

GlobeNewsWire
Neutral
Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development
2021-08-18 08:00

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced it has selected a fourth core inhibitor candidate, ABI-4334 (4334), that has been optimized for potency, to advance into clinical development. The company is conducting preclinical work, with the aim of completing regulatory filings and initiating clinical studies as soon as possible in 2022.

Zacks Investment Research
Negative
Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates
2021-08-05 19:01

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire
Neutral
Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights
2021-08-05 16:01

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today reported financial results and recent highlights for the second quarter ended June 30, 2021.

GlobeNewsWire
Neutral
Assembly Bio Announces Key Promotions to Leadership Team
2021-08-03 08:00

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced the promotions of Jason Okazaki to chief operating officer and Michael Samar to chief financial officer. Mr. Okazaki joined Assembly Bio in 2020 as chief legal and business officer responsible for leading and executing strategic collaborations and transactions. Since joining Assembly Bio in 2017, Mr. Samar has led the company's financial and business operations, serving most recently as senior vice president of finance and business operations.

Loading more news...